A new study published in The BMJ found that GLP-1 receptor agonists, used for type 2 diabetes and weight loss, were linked to a lower risk of substance use. This includes substances such as alcohol, nicotine, cannabis, cocaine, and opioids. Analysis of over 6,00,000 US veterans also showed fewer addiction-related hospital visits, overdoses and deaths among users.